IDEXX Laboratories reported fourth‑quarter 2025 revenue of $1.091 billion, up 14% year‑over‑year and 12% on an organic basis, and earnings per diluted share of $3.08, a 18% increase from the prior year and a 17% rise on a comparable basis. The $0.15 earnings beat—about 5.2% above the consensus estimate of $2.93—was driven by disciplined cost management and a favorable mix shift toward high‑margin consumables, which helped offset modest price pressure in some legacy product lines.
Revenue growth was led by the Companion Animal Group, which generated $998 million in the quarter, up 15% reported and 13% organically, reflecting strong demand for diagnostic and treatment solutions in the pet‑care market. The Water segment also expanded, contributing 12% growth, while the remaining segments delivered steady performance. The mix shift toward consumables and laboratory services—businesses that generate recurring revenue—contributed to the overall revenue lift and supported margin expansion.
Operating margin rose to 28.9% from 27.7% a year earlier, an increase of 120 basis points on a comparable basis. The margin expansion was largely attributable to higher pricing power in the consumables portfolio and improved operational leverage as revenue scales. Gross margin reached 60.3%, up 50 basis points, driven by volume gains and productivity initiatives that reduced cost of goods sold relative to revenue growth.
For the full year, IDEXX posted revenue of $4.304 billion, a 10% increase on an organic basis, and earnings per share of $13.08, up 23% on a reported basis. Year‑over‑year revenue growth accelerated from 6% in Q4 2024 to 14% in Q4 2025, underscoring the company’s ability to capture demand across its core segments. Full‑year EPS growth of 23% also outpaced the 14% comparable‑basis increase, reflecting the company’s focus on high‑margin products and disciplined cost control.
Management raised 2026 revenue guidance to $4.632–$4.720 billion and EPS guidance to $14.29–$14.80, an upward revision that signals confidence in continued demand and margin expansion. CEO Jay Mazelsky highlighted the company’s innovation‑driven growth strategy, noting that new platform launches and a solid foundation of recurring revenue underpin the outlook. CFO Andrew Emerson emphasized that the guidance reflects both organic growth and the benefits of pricing power in high‑margin consumables.
Investors reacted cautiously to the results, with market sentiment tempered by IDEXX’s premium valuation and the perception that the forward guidance, while in line with consensus, did not provide a significant upside. The company’s strong earnings beat and margin expansion, however, reinforce its competitive position in the veterinary diagnostics market and suggest resilience amid macro‑economic headwinds.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.